| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5590816 | Multiple Sclerosis and Related Disorders | 2017 | 7 Pages |
Abstract
Improvements in patient-reported physical and psychological functioning and general health status with daclizumab compared with intramuscular interferon beta-1a are consistent with outcomes on clinical and brain MRI lesion measures in DECIDE (NCT01064401).
Keywords
EQ-5DMSIS-29BDI-IIRRMsQOLARRVASQuality of lifeMRIinterferonIFNrelapsing-remittingMagnetic resonance imagingDaclizumabsubcutaneousIntramuscularPhysvisual analog scalerelapsing-remitting multiple sclerosisMultiple sclerosisPatient-reported outcomespatient-reported outcomeannualized relapse ratePROodds ratioBeck Depression Inventory-II
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Genetics
Authors
Ying Liu, Timothy Vollmer, Eva Havrdova, Katherine Riester, Andrew Lee, Glenn Phillips, Ping Wang, Guido Sabatella,